NEW YORK—The Fidelity MSCI Health Care Index ETF (FHLC) and the iShares U.S. Healthcare ETF (IYH) deliver similar five-year returns through radically different portfolio construction, and that gap matters more than most investors realize.
FHLC holds 334 positions. IYH holds 100. Despite that structural difference, both funds posted comparable five-year returns—a result that points to one likely explanation: a handful of dominant healthcare giants carry enough weight in both portfolios to drive collective performance regardless of how many smaller names sit below them.
FHLC's breadth reduces exposure to any single stock's volatility. IYH's concentration means each holding moves the needle more. Investors who want to reduce idiosyncratic risk should lean toward FHLC. Those willing to accept that concentration in exchange for sharper upside from a select group of leaders have a case for IYH.
The sector's underlying demand story remains intact. An aging population, expanding access to medical care, and advances in pharmaceuticals, biotechnology and medical devices continue to generate revenue across sub-sectors. Gene therapy, AI-powered diagnostics and personalized medicine are creating new growth vectors for industry leaders—catalysts that matter most to the large-cap names anchoring both funds.
Key near-term catalysts to watch: quarterly earnings from major drugmakers and device companies, FDA approval decisions that can move individual names sharply, and M&A activity in biotechnology, which has historically driven sector re-ratings.
The broader U.S. equity market rose today, with the Nasdaq gaining 1.0 percent to 25,374 and the S&P 500 climbing 0.7 percent to 7,490.
The choice between FHLC and IYH ultimately comes down to risk tolerance and research capacity. FHLC is the better fit for investors who want full sector coverage without the homework. IYH suits investors with a view on which large-cap healthcare names will outperform—and the conviction to back it.
